GeoVax Labs (GOVX) Q3 2024 earnings summary

Executive summary

• Secured a BARDA Project NextGen Award of nearly $400 million to support a 10,000-patient Phase 2b COVID-19 vaccine trial, with all study sites selected and manufacturing underway.

• Advanced Gedeptin therapy for recurrent head and neck cancer, with Phase 1/2 trials completed and Phase 2 trial initiation planned for H1 2025.

• Progressed GEO-MVA mpox/smallpox vaccine program, with cGMP clinical batch production expected by year-end and ongoing regulatory engagement.

• Strengthened business development and balance sheet through increased partnering activities and multiple financings, improving stockholders' equity and Nasdaq compliance.

• Company operates as a clinical-stage biotech focused on vaccines and immunotherapies for infectious diseases and cancer.

Financial highlights

• Q3 2024 revenue was $2.8 million, and nine-month revenue was $3.1 million, all from the BARDA contract; no comparable revenue in 2023.

• Net loss for Q3 2024 was $5.8 million ($0.91/share), improved from $8.4 million ($4.75/share) in Q3 2023; nine-month net loss was $16.7 million ($4.52/share), down from $18.4 million ($10.42/share) in 2023.

• R&D expenses for Q3 2024 were $7.4 million, up from $6.9 million in Q3 2023; nine-month R&D was $16.1 million, up 11% year-over-year.

• General and administrative expenses decreased 17% for the nine months, primarily from lower stock-based compensation.

• Cash balance at September 30, 2024, was $8.6 million, up from $6.5 million at year-end 2023.

Outlook and guidance

• BARDA Project NextGen trial enrollment projected to begin in early October 2025, with full enrollment expected within six months.

• Interim results for COVID-19 vaccine trials and final results for the healthy volunteer booster trial anticipated by year-end 2024 or early 2025.

• Gedeptin Phase 2 trial initiation planned for H1 2025.

• Existing cash is expected to fund operations into Q1 2025; additional capital will be sought through equity, debt, grants, or partnerships.

• Continued focus on advancing Gedeptin, GEO-CM04S1, and GEO-MVA programs, with capital formation plans in place to fund key milestones.